SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Orbifloxacin Liquid Formulation

Manufacturer or supplier’s details
Company : MSD
Address : Rua Coronel Bento Soares, 530 Cruzeiro - Sao Paulo - Brazil CEP 12730-340
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com
Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard
Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Eye)

GHS label elements in accordance with ABNT NBR 14725 Standard
Hazard pictograms : ![Image of Warning Pictogram]
Signal Word : Warning
Hazard Statements : H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.
Precautionary Statements : Prevention:
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Version 4.0  Revision Date: 23.03.2020  SDS Number: 785423-00011  Date of last issue: 13.09.2019
Date of first issue: 28.06.2016

Storage:
P405 Store locked up.

Other hazards which do not result in classification
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>Acute toxicity (Oral), Reproductive toxicity, Category 2</td>
<td>&gt;= 3 &lt;- 5</td>
</tr>
<tr>
<td>Lactic acid</td>
<td>50-21-5</td>
<td>Acute toxicity (Oral), Skin irritation, Category 2</td>
<td>&gt;= 1 &lt;- 3</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>Corrosive to Metals, Skin corrosion, Category 1A</td>
<td>&gt;= 1 &lt;- 2</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms : Suspected of damaging the unborn child.
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Version 4.0
Revision Date: 23.03.2020
SDS Number: 785423-00011
Date of last issue: 13.09.2019
Date of first issue: 28.06.2016

and effects, both acute and delayed
Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting
Hazardous combustion products: Carbon oxides
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding
SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Avoid inhalation of vapor or mist.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>C</td>
<td>2 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures:
- Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
- Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or
exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Combined particulates and organic vapor type
Hand protection Material: Chemical-resistant gloves
Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection: Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: suspension
Color: light brown
Odor: odorless
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): Not applicable
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapor pressure: No data available
Relative vapor density: No data available
Relative density: No data available
Density: No data available
Solubility(ies) Water solubility: No data available
Partition coefficient: n-octanol/water : No data available
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
  Skin contact
  Ingestion
  Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
  Method: Calculation method

Components:
Orbifloxacin:
Acute oral toxicity : LD50 (Rat): > 3.000 mg/kg
  Remarks: No mortality observed at this dose.
  LD50 (Mouse): > 2.000 mg/kg
  Remarks: No mortality observed at this dose.
  LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration): LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Lactic acid:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Sodium hydroxide:
Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation
Not classified based on available information.

Product:
Species : Rabbit
Result : No skin irritation

Components:
Orbifloxacin:
Species : Rabbit
Method : Draize Test
Result : No skin irritation

Lactic acid:
<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Skin irritation</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
<tr>
<td>Sodium hydroxide:</td>
<td></td>
</tr>
<tr>
<td>Result</td>
<td>Corrosive after 3 minutes or less of exposure</td>
</tr>
</tbody>
</table>

**Serious eye damage/eye irritation**
Not classified based on available information.

**Product:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild eye irritation</td>
</tr>
</tbody>
</table>

**Components:**

### Orbifloxacin:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild eye irritation</td>
</tr>
<tr>
<td>Method</td>
<td>Draize Test</td>
</tr>
</tbody>
</table>

### Lactic acid:

<table>
<thead>
<tr>
<th>Species</th>
<th>Chicken eye</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Irreversible effects on the eye</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

| Sodium hydroxide: | |
| Result | Irreversible effects on the eye |
| Remarks | Based on skin corrosivity. |

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Product:**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Magnusson-Kligman-Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routes of exposure</td>
<td>Dermal</td>
</tr>
<tr>
<td>Species</td>
<td>Guinea pig</td>
</tr>
<tr>
<td>Result</td>
<td>Not a skin sensitizer.</td>
</tr>
</tbody>
</table>

**Components:**

### Orbifloxacin:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Maximization Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routes of exposure</td>
<td>Dermal</td>
</tr>
<tr>
<td>Species</td>
<td>Guinea pig</td>
</tr>
<tr>
<td>Result</td>
<td>Not a skin sensitizer.</td>
</tr>
</tbody>
</table>
Lactic acid:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Buehler Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routes of exposure</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Species</td>
<td>Guinea pig</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Sodium hydroxide:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Human repeat insult patch test (HRIPT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routes of exposure</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity

Not classified based on available information.

Components:

Orbifloxacin:

Genotoxicity in vitro:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method</td>
<td>OECD Test Guideline 471</td>
</tr>
<tr>
<td>Result</td>
<td>equivocal</td>
</tr>
<tr>
<td></td>
<td>Mouse Lymphoma</td>
</tr>
<tr>
<td></td>
<td>positive</td>
</tr>
<tr>
<td></td>
<td>Chromosomal aberration</td>
</tr>
<tr>
<td></td>
<td>Human lymphocytes</td>
</tr>
<tr>
<td></td>
<td>positive</td>
</tr>
</tbody>
</table>

Genotoxicity in vivo:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Micronucleus test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Cell type</td>
<td>Bone marrow</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intraperitoneal injection</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity - Assessment:

Weight of evidence does not support classification as a germ cell mutagen.

Lactic acid:

Genotoxicity in vitro:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method</td>
<td>OECD Test Guideline 471</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

**Orbifloxacin:**

- **Species:** Rat
- **Application Route:** Oral
- **Exposure time:** 2 Years
- **NOAEL:** 200 mg/kg body weight
- **Result:** negative

- **Species:** Mouse
- **Application Route:** Oral
- **Exposure time:** 2 Years
- **NOAEL:** 200 mg/kg body weight
- **Result:** negative

**Lactic acid:**

- **Species:** Rat
- **Application Route:** Ingestion
- **Exposure time:** 2 Years
- **Result:** negative
- **Remarks:** Based on data from similar materials

**Reproductive toxicity**
Suspected of damaging the unborn child.

Components:

**Orbifloxacin:**

- **Effects on fertility**
  - **Test Type:** Two-generation reproduction toxicity study
  - **Species:** Rat
  - **Application Route:** Oral
  - **General Toxicity Parent:** NOAEL: 50 mg/kg body weight
  - **Early Embryonic Development:** NOAEL: 50 mg/kg body weight
  - **Result:** No adverse effects.

- **Effects on fetal development**
  - **Test Type:** Embryo-fetal development
  - **Species:** Rat
  - **Application Route:** Oral
  - **Embryo-fetal toxicity:** LOAEL: 333 mg/kg body weight
  - **Result:** No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses.
Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-fetal toxicity: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain.

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2,5 mg/kg body weight
Result: Effects on postnatal development, Skeletal malformations.

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

Lactic acid:
Effects on fetal development: Test Type: Embryo-fetal development
Species: Mouse
Application Route: Ingestion
Result: negative

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Product:
Target Organs: Eye
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Product:
Species: Dog
NOAEL: 22,5 mg/kg
LOAEL: 37,5 mg/kg
Application Route: Oral
Exposure time: 30 Days
Symptoms: Gastrointestinal disturbance

Species: Dog
LOAEL: 75 mg/kg
Application Route: Oral
Exposure time: 10 Days
Symptoms: Salivation, Gastrointestinal disturbance, Vomiting
SAFETY DATA SHEET

Or bifloxacin Liquid Formulation

Species: Cat
LOAEL: 45 mg/kg
Application Route: Oral
Exposure time: 30 Days
Target Organs: Eye
Symptoms: Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders

Components:

Or bifloxacin:
Species: Rat
NOAEL: 20 mg/kg
LOAEL: 80 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: Testis, Liver, Kidney, spleen

Species: Mouse
NOAEL: 80 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 3 Months

Species: Juvenile dog
NOAEL: 50 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 14 Days
Target Organs: Heart, Bone
Symptoms: Gastrointestinal disturbance
Remarks: mortality observed

Species: Juvenile dog
NOAEL: 2 mg/kg
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 90 Days
Target Organs: Bone
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 37,5 mg/kg
Application Route: Oral
Exposure time: 30 Days

Species: Cat
NOAEL: 7,5 mg/kg
LOAEL: 22,5 mg/kg
Application Route: Oral
Exposure time: 1 Months
Symptoms: Gastrointestinal disturbance
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Version: 4.0  Revision Date: 23.03.2020  SDS Number: 785423-00011  Date of last issue: 13.09.2019
Date of first issue: 28.06.2016

### Lactic acid:
- **Species**: Rat
- **NOAEL**: > 100 mg/kg
- **Application Route**: Ingestion
- **Exposure time**: 13 Weeks
- **Remarks**: Based on data from similar materials

### Species
- **Application Route**: Skin contact
- **Exposure time**: 13 Weeks

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

### Orbifloxacin:
- **Ingestion**: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
  - **Remarks**: May cause photosensitization

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

### Components:

**Lactic acid:**
- **Toxicity to fish**
  - LC50 (Danio rerio (zebra fish)): > 100 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
  - Remarks: Based on data from similar materials

- **Toxicity to daphnia and other aquatic invertebrates**
  - EC50 (Daphnia magna (Water flea)): > 100 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
  - Remarks: Based on data from similar materials

- **Toxicity to algae/aquatic plants**
  - ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials

- **Toxicity to microorganisms**
  - EC50: > 10 - 100 mg/l
  - Exposure time: 3 h

- **NOEC (Pseudokirchneriella subcapitata (green algae))**: > 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials
Persistence and degradability

Components:

Lactic acid:
Biodegradability: Result: Not readily biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Lactic acid:
Partition coefficient: n-octanol/water: log Pow: -0.62

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

ANTT
Not regulated as a dangerous good
SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Sodium hydroxide

International Regulations

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information


Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / C : Ceiling limit

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships;
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

BR / Z8